Metformin exerts multitarget antileukemia activity in JAK2(V617F)-positive myeloproliferative neoplasms

The recurrent gain-of-function JAK2(V617F) mutation confers growth factor-independent proliferation for hematopoietic cells and is a major contributor to the pathogenesis of myeloproliferative neoplasms (MPN). The lack of complete response in most patients treated with the JAK1/2 inhibitor ruxolitin...

Descripción completa

Detalles Bibliográficos
Autores principales: Machado-Neto, João Agostinho, Fenerich, Bruna Alves, Scopim-Ribeiro, Renata, Eide, Christopher A., Coelho-Silva, Juan Luiz, Dechandt, Carlos Roberto Porto, Fernandes, Jaqueline Cristina, Rodrigues Alves, Ana Paula Nunes, Scheucher, Priscila Santos, Simões, Belinda Pinto, Alberici, Luciane Carla, de Figueiredo Pontes, Lorena Lôbo, Tognon, Cristina E., Druker, Brian J., Rego, Eduardo Magalhães, Traina, Fabiola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833553/
https://www.ncbi.nlm.nih.gov/pubmed/29472557
http://dx.doi.org/10.1038/s41419-017-0256-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5833553/
https://www.ncbi.nlm.nih.gov/pubmed/29472557
http://dx.doi.org/10.1038/s41419-017-0256-4

Ejemplares similares